UroGen Pharma Ltd. logo

UroGen Pharma Ltd.

URGN | NASDAQ
Chart Builder DCF Calculator
$43.20
-$0.05 (-0.12%)
At close: Sep 21, 2026, 4:00 PM ET
$44.20
+$1 (+2.31%)
After-hours: Sep 21, 2026, 7:30 PM ET

Market Data

Market Cap
$2.11B
Enterprise Value
$2.19B
Beta
1.58
Average Volume
826.36K
Shares Outstanding (Diluted)
50.38M
Shares Change YoY
5.53%
Institutional Ownership
92.55%
Exchange
NASDAQ
ISIN
IL0011407140

Price Performance

Price Change 1M
-7.6%
Price Change 3M
22.9%
Price Change 6M
138.4%
Price Change YTD
90.2%
Price Change 1Y
140.1%
Price Change 3Y
175.3%
Price Change 5Y
154.9%
1M CAGR (ann.)
-5.2%
1Y CAGR (ann.)
138.9%
5Y CAGR (ann.)
22.0%
All-Time CAGR
12.8%

Valuation

PE Ratio
-21.82
Forward PE
14.15
PEG Ratio
-0.43
Forward PEG
0.02
PS Ratio
11.15
Forward PS
3.90
PB Ratio
-15.90
P/FCF Ratio
-10.29
P/Adj. FCF Ratio
-9.34
P/OCF Ratio
-13.71
EV/Sales
11.62
EV/EBIT
-30.14
EV/EBITDA
-31.01
EV/FCF
-10.72
Earnings Yield
-4.6%
FCF Yield
-9.7%
Adj. FCF Yield
-10.7%

Financial Health

Net Debt
$80.76M
Total Debt
$196.13M
Cash & Short-Term Investments
$107.98M
Total Assets
$252.59M
Current Ratio
3.80
Quick Ratio
3.41
Debt / Equity Ratio
-1.48
Debt / EBITDA
-2.77
Debt / FCF
-0.96
OCF / Debt
-1.04
Interest Coverage
-1.93
Altman Z-Score
-1.62
Piotroski F-Score
3

Margins & Profitability

Gross Profit Margin
90.8%
Operating Profit Margin
-35.3%
EBITDA Margin
-37.5%
Net Profit Margin
-51.7%
FCF Margin
-108.4%
Adj. FCF Margin
-119.3%
SBC / Revenue
8.5%
SBC Impact (per share)
-10.1%

Returns

Return on Assets
-38.6%
Return on Equity
81.8%
Return on Invested Capital
-34.4%
Return on Capital Employed
-35.0%
Return on Tangible Assets
-38.6%

Historical Growth (CAGR)

Revenue CAGR 3Y
37.5%
Revenue CAGR 5Y
42.7%
Revenue CAGR 10Y
30.5%
EPS CAGR 3Y
22.7%
EPS CAGR 5Y
20.5%
EPS CAGR 10Y
-0.8%
FCF CAGR 3Y
-42.9%
FCF CAGR 5Y
-23.7%
FCF CAGR 10Y
-19.3%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
16
EPS Growth Next 3Y
147.1%
Revenue Growth Next 3Y
64.0%
Earnings Date
Nov 4, 2026
EPS Estimate (next Q)
$0.10
EPS Growth Est (next Q)
-114.9%
Revenue Est (next Q)
$90.58M
Revenue Growth Est (next Q)
229.6%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$56.60
Price Target Upside
31.0%

Cash Flow

Operating Cash Flow
$-204.23M
Free Cash Flow
$-204.51M
Adj. Free Cash Flow
$-225.25M
FCF Per Share
-$3.16
OCF Per Share
-$3.15
OCF/S Ratio
-84.2%

Income Statement

Revenue
$188.73M
Gross Profit
$171.46M
Operating Income
$-66.65M
EBITDA
$-70.72M
Net Income
$-97.64M
EPS (Diluted)
-$1.98
Revenue / Employee
$629.11K
Profit / Employee
$-325.45K
Employees
300

© 2026 bestshares.com. All rights reserved.